Japanese Journal of Clinical Oncology 34:20-28 (2004)
© 2004 Foundation for Promotion of Cancer Research
Superior Anti-tumor Efficacy of Bicalutamide 80 mg in Combination with a Luteinizing Hormone-releasing Hormone (LHRH) Agonist Versus LHRH Agonist Monotherapy as First-line Treatment for Advanced Prostate Cancer: Interim Results of a Randomized Study in Japanese Patients
1 Department of Urology, Institute of Clinical Medicine, University of Tsukuba, Tsukuba, Ibaraki, 2 Department of Urology, Harasanshin Hospital, Fukuoka, 3 Department of Urology, Kansai Medical University, Osaka, 4 Department of Urology, Shimane Medical University, Izumo, Shimane, 5 Department of Urology, Okayama University Graduate School of Medicine, Okayama, 6 Department of Urology, Nishi-Kobe Medical Center, Kobe, 7 Department of Urology, Tohoku University School of Medicine, Sendai, 8 Department of Urology, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, 9 Department of Urology, Kyushu University, Fukuoka, 10 Department of Urology, Nagasaki University School of Medicine, Nagasaki and 11 Department of Biostatistics, School of Health Sciences and Nursing, The University of Tokyo, Tokyo, Japan
Objectives: To evaluate bicalutamide (Casodex) 80 mg as a component of maximum androgen blockade (MAB) in Japanese patients with previously untreated advanced prostate cancer.
Methods: 205 patients with previously untreated stage C/D prostate cancer were randomized (1:1) to receive once-daily bicalutamide 80 mg or placebo, each combined with a luteinizing hormone-releasing hormone (LHRH) agonist. Primary study variables were the 12 week prostate-specific antigen (PSA) normalization (i.e. PSA level 
4 ng/ml) rate, the 12 week overall tumor response rate (proportion with a partial response or better) and the proportion of withdrawals due to adverse drug reactions (ADRs) at follow-up. This interim analysis was undertaken after a minimum of 6 months’ follow-up (median 15 months).
Results: The 12 week PSA normalization rate was 79.4% for MAB and 38.6% for LHRH agonist monotherapy (P < 0.001). The 12 week overall tumor response rate was 77.5 and 65.3%, respectively (P = 0.063). The withdrawal rate due to ADRs was 8.8% and 10.9%, respectively. There were differences in favor of MAB over monotherapy with respect to time to treatment failure (TTTF) (P = 0.038) and time to progression (TTP) (P = 0.016). There have been too few deaths (n = 10) to analyze survival. The profiles of adverse events and ADRs were broadly similar in the two treatment groups.
Conclusion: In Japanese patients with advanced prostate cancer, first-line treatment with bicalutamide 80 mg in combination with an LHRH agonist is superior to LHRH agonist monotherapy in terms of the antitumor response at 12 weeks, and also time to treatment failure and progression, and does not compromise treatment safety. The study is ongoing.
+ For reprints and all correspondence: Hideyuki Akaza, Department of Urology, Institute of Clinical Medicine, University of Tsukuba, Tsukuba City, Ibaraki 305-8575, Japan. E-mail: akazah{at}md.tsukuba.ac.jp
Casodex and Zoladex are trademarks of the AstraZeneca group of companies.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  D. A. Loblaw, K. S. Virgo, R. Nam, M. R. Somerfield, E. Ben-Josef, D. S. Mendelson, R. Middleton, S. A. Sharp, T. J. Smith, J. Talcott, et al. Initial Hormonal Management of Androgen-Sensitive Metastatic, Recurrent, or Progressive Prostate Cancer: 2007 Update of an American Society of Clinical Oncology Practice Guideline J. Clin. Oncol., April 20, 2007; 25(12): 1596 - 1605. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F Labrie, V Luu-The, A Belanger, S-X Lin, J Simard, G Pelletier, and C Labrie Is dehydroepiandrosterone a hormone? J. Endocrinol., November 1, 2005; 187(2): 169 - 196. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Labrie, A. Belanger, V. Luu-The, C. Labrie, J. Simard, L. Cusan, J. Gomez, and B. Candas Gonadotropin-Releasing Hormone Agonists in the Treatment of Prostate Cancer Endocr. Rev., May 1, 2005; 26(3): 361 - 379. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. E. Bohl, W. Gao, D. D. Miller, C. E. Bell, and J. T. Dalton Structural basis for antagonism and resistance of bicalutamide in prostate cancer PNAS, April 26, 2005; 102(17): 6201 - 6206. [Abstract] [Full Text] [PDF]
|
|